TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age.~* Scheduled to total hysterectomy + bilateral salpingooophorectomy (BSAE) and peritoneal lavage because of endometrial carcinoma, International federation of gynecology and obstetrics (FIGO) stage 1, grade 1 and 2, with diploid DNA profile (i.e. low risk profile).~* WHO (World Health Organisation) performance status ≤ 2.~* Proficiency in Swedish~* Accept to participate in the study and has signed written informed consent document.~* The operation should be considered possible to be perform laparoscopically and by laparotomy through a low transverse abdominal wall incision.~Exclusion Criteria:~* The operation is anticipated to comprise more than the hysterectomy + BSAE.~* A midline incision is planned for the laparotomy.~* Contraindications towards spinal anesthesia with intrathecally applied morphine.~* Physically disabled women who cannot be expected to be mobilized in accordance to the fast track program in a way similar to what is expected from not-physically disabled women.~* Mentally disabled women who cannot fill in the questionnaires or understand the consequences of participating in a trial.~* Severe psychiatric disease or on medication for psychiatric disease so that the physician consider participation in the trial inappropriate.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abdominal total hysterectomy (Type: ACTIVE_COMPARATOR): Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
- Robot assisted laparoscopic hysterectomy (Type: ACTIVE_COMPARATOR): Robot assisted laparoscopic total hysterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kaiser Permanente HIV Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~HIV infection.~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIV infected (Type: None): No study specific intervention, non-interventional trial
- HIV-uninfected (Type: None): No study specific intervention, non-interventional trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with LDL-C \>70 mg/dL \& on a stable dose of atorvastatin 40 mg~Exclusion Criteria:~* Pregnant or lactating women or intending to become pregnant~* Patient with sensitivity or intolerance to ezetimibe or atorvastatin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Atorvastatin 80 mg
- 2 (Type: EXPERIMENTAL): Atorvastatin 40 mg + ezetimibe 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with lumbar disc herniation (L4-L5 or L5-S1) as assessed by MRI and clinical symptoms corresponding to position of the impaired nerve root~* Patients assessed as positive in the SLR test~* Patients with sciatica in either lower leg~* Patients with no improvement from pharmacotherapy or concomitant treatment with drug and nerve block~Exclusion Criteria:~* Patients who have 2 or more lumbar disc herniations as assessed by MRI~* Patients with extrusion-type or sequestration-type herniation in whom a rupture into the posterior longitudinal ligament is identified by MRI~* Patients who have received nerve block within 3 weeks before screening~* Patients who have undergone lumbar operation, chemonucleolysis, or percutaneous nucleotomy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): None
- II (Type: EXPERIMENTAL): None
- III (Type: EXPERIMENTAL): None
- IV (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Effect of Estrogens Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women without menstrual cycles within the last 12 months and FSH \> 30IU/L~* Healthy women~* Women that were not using drugs with potential vascular effect within the last 1 year~* Women that never used hormone replacement therapy~Exclusion Criteria:~* Smoking~* Blood Pressure \> 160/90 mm Hg.~* Breast and or endometrial cancer~* History of acute myocardial infarction~* Diabetes~* Vaginal bleeding of any origin~* Hepatic disease~* Thrombophlebitis or thromboembolic disorders

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Estrogen use (Type: EXPERIMENTAL): climacteric women will use conjugated equine estrogens
- use of Placebo (Type: PLACEBO_COMPARATOR): climacteric women will use placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valproic Acid in Treating Cyanotic Breath Holding Spells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~1. Children with high frequency spells (≥ 4/week) of CBHS.~2. Children with parents who were wishing to provide treatment to their children.~3. Failure of alternatives modalities of treatment (e.g. iron supplements, piracetam, non-specific vitamins, etc) (tried for ≥ 3 months) to reduce the frequency of spells or stop them.~4. Follow-up for 6 months after starting treatment with valproic acid.~Exclusion criteria:~1. Primary neurologic disease, history of epilepsy or febrile convulsions, abnormal neurological examination and abnormal EEG.~2. Primary cardiac disease or presence of long QT syndrome in the ECG.~3. Presence of a hematologic (other than IDA) or other medical disease, electrolyte disturbance, hypoglycemia, hypocalcemia, impaired kidney or liver function tests.~4. Those with a doubtful diagnosis.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- cyanotic breath holding spells (Type: OTHER): drug, valproic acid: 5mg/kg/d for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is in good physical health-~* Participant's parent/legal guardian is able to read, understand, and complete the vaccine report card~* Participant's parent/legal guardian agrees to provide a phone number for follow-up purposes~* Participant is not sexually active and does not plan to become sexually active during the time from Day 1 to Month 7 of the study~Exclusion Criteria:~* Participant has a history of severe allergic reaction that required medical intervention~* Participant has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection~* Participant is pregnant~* Participant intends to donate blood during the time from Day 1 to Month 7 of the study~* Participant is immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.~* Participant has had a splenectomy~* Participant has received any of the following immunosuppressive therapies in the year prior to enrollment: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (Arava), tumor necrosis factor alpha (TNF-α) antagonists, monoclonal antibody therapies, antilymphocyte sera, or other therapy known to interfere with the immune response.~* Participant has received any immune globulin product or blood-derived product in the three months prior to the Day 1 vaccination, or plans to receive any such product through Month 7 of the study~* Participant has received any inactivated vaccines within 14 days of the Day 1 vaccination or any live vaccines within 28 days of the Day 1 vaccination~* Participant has received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial~* Participant has had a fever (oral temperature ≥37.8°C) within 24 hours of the Day 1 vaccination~* Participant has a history of a positive test for HPV or history of genital warts

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- All Enrolled (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet the Migraine diagnosis.~* Age of onset should be before age 50 years.~* Migraine must have been occurring for 1 year preceding entry into the trial.~* The number of migraine attack should be no less than 6 for a period of 3 months prior to Screening stage.~* The number of migraine days is to be 2-8 for a period of 1 month prior to screening for entry into the trial.~* Migraine days should be less than 15 for a period of 1 month prior to screening for entry into the trial.~* Ages 18-65.~* Participant can understand and complete the Headache diary.~* All participants signed the informed consent.~Exclusion Criteria:~* Other migraine prophylactic medication is continued 3 months prior to the drug trial.~* Participants who have taken Tianshu capsule during 1 month prior to Screening stage.~* The number of acute treatment for migraine is more than 10 per month.~* Participants who have taken antipsychotics or antidepressant medications (unless only for migraine prophylaxis) during the previous 3 months.~* Participants who abuse alcohol or other drugs.~* Participants who are resistant to all acute migraine drugs prescribed optimally.~* hypotension or uncontrolled hypertension.~* Severe infections.~* Malignancy.~* Significant medical history of such as cardiac disease, cerebrovascular disease, liver disease, nephropathy etc.~* Known allergies or serious side effects with Tianshu capsule in the past.~* Breastfeeding, pregnant and potentially fertile women participant.~* History of cluster headaches, tension-type headache, vascular headache with non-migraine, drug - dependence headache.~* Secondary headaches, including hypertension, post-traumatic brain syndrome etc.~* Participants who have taken migraine prophylactic medication regularly during 1 month prior to Screening stage.~* Participants who are taking part in other clinical trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tianshu capsule (Type: EXPERIMENTAL): Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
- Sugar pill (Type: PLACEBO_COMPARATOR): Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CS-3150 in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 20 years or older at informed consent~* Subjects with essential hypertension satisfying the following blood pressure criteria;~  * Sitting SBP: ≥ 140 mmHg and \< 180 mmHg~ * Sitting DBP: ≥ 90 mmHg and \< 110 mmHg~ * Mean 24 hr BP: SBP ≥ 130 and DBP ≥ 80 mmHg~Exclusion Criteria:~* Secondary hypertension or malignant hypertension~* Diabetic nephropathy or diabetes mellitus with albuminuria~* Serum potassium level \< 3.5 or ≥ 5.1 mEq/L~* Reversed day-night life cycle including overnight workers~* eGFR \< 60 mL/min/1.73 m\^2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-3150 2.5 mg (Type: EXPERIMENTAL): CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
- CS-3150 5.0 mg (Type: EXPERIMENTAL): CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Identified as having an acute exacerbation of COPD within 24 hours of admission~Exclusion Criteria:~* Death during the index encounter~* No initial discharge as of the end of the study period

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: OTHER): Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
- Intervention (Type: OTHER): A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Have a body mass index between 20.0 and 29.9 kg/m², inclusive.~Exclusion Criteria:~* History and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference investigational product formulation or comparable drugs~* Active or latent Tuberculosis or who have a history of Tuberculosis~* History of invasive systemic fungal infections or other opportunistic infections~* Systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process~* Serious infection associated with hospitalisation and/or which required intravenous antibiotics~* History of and/or current cardiac disease~* Have received live vaccine(s) within 4 weeks prior to Screening or who will require live vaccine(s) between Screening and the final study visit~* Intake medication with a half-life \> 24 h within 4 weeks or 10 half-lives of the medication prior to investigational product administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SB5 (Type: EXPERIMENTAL): SB5, single dose of 40 mg via subcutaneous injection (study drug)
- EU sourced Humira® (Type: ACTIVE_COMPARATOR): EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
- US sourced Humira® (Type: ACTIVE_COMPARATOR): US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).~Exclusion Criteria:~* Clinically unstable patients (e.g. intensive care unit)~* Renal insufficiency~* Patients undergoing a relevant change in chemotherapy \</= 48 hours prior to and up to 24 hours after the administration of Gadovist.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
- Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
- Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
- Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed HER2-positive MBC~* Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery~* Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment~* Stable systemic disease~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* LVEF at least 50%~* Adequate hematologic, renal, and hepatic function~* Life expectancy more than 12 weeks~Exclusion Criteria:~* Progression of systemic disease at Screening~* Leptomeningeal disease~* History of intolerance or hypersensitivity to study drug~* Use of certain investigational therapies within 21 days prior to enrollment~* Current anthracycline use~* Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use~* Active infection~* Pregnant or lactating women~* Significant history or risk of cardiac disease~* Symptomatic intrinsic lung disease or lung involvement~* History of other malignancy within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertuzumab + Trastuzumab (Type: EXPERIMENTAL): Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete